Agere Pharmaceuticals has added cGMP manufacturing capabilities to support clients entering Phase IIb trials. The new capacity extends services for formulation development to oral bioavailability of BCS II and IV compounds.     “We’ve extended our cGMP spray drying capabilities in response to our clients’ requests to continue with Agere as they enter Phase IIb clinical trials,” said Marshall Crew, Agere’s president and chief executive officer. “This is a natural progression for us, as expanding ...